NCT04743557View on ClinicalTrials.gov

Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies

PHASE1/PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions

Centronuclear Myopathy

Interventions

DRUG

DYN101

DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA

Trial Locations (2)

45122

Universitätsklinikum Essen, Essen

75012

I-Motion Institute - Trousseau Hospital, Paris

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Dynacure

INDUSTRY